Suchergebnisse - "Mandalà, Mario"

PubPharm (17)

1

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

enthalten in: Cancer management and research | 2023

von Quaglino, P. | Ascierto, P. | Consoli, F. | +14

2

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Dummer, R. | Long, G. | Robert, C. | +22

CommentIn: J Clin Oncol. 2022 May 1;40(13):1393-1395. - PMID 35030031

3

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-i

enthalten in: Nature medicine | 2020

von Dummer, R. | Lebbé, C. | Atkinson, V. | +18

4

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

enthalten in: The New England journal of medicine | 2020

von Dummer, R. | Hauschild, A. | Santinami, M. | +18

5

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD) : exploratory biomarker analyses from a randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2020

von Dummer, R. | Brase, J. | Garrett, J. | +16

CommentIn: Lancet Oncol. 2020 Mar;21(3):319-320. - PMID 32007137

6

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

enthalten in: The New England journal of medicine | 2019

von Robert, C. | Grob, J. | Stroyakovskiy, D. | +23

CommentIn: Strahlenther Onkol. 2019 Oct;195(10):940-942. - PMID 31418045

7

Reply to E. Hindié and K.R. Hess

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Long, G. | Dummer, R. | Schadendorf, D. | +20

CommentOn: J Clin Oncol. 2018 Oct 22;:JCO1801219. - PMID 30343620

8

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) : a randomised, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Schadendorf, D. | Hauschild, A. | Santinami, M. | +20

CommentIn: Lancet Oncol. 2019 May;20(5):611-612. - PMID 30928621

9

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Hauschild, A. | Dummer, R. | Schadendorf, D. | +20

CommentIn: J Clin Oncol. 2019 May 20;37(15):1356-1358. - PMID 30939092

10

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

enthalten in: The New England journal of medicine | 2017

von Long, G. | Hauschild, A. | Santinami, M. | +20

CommentIn: Nat Rev Clin Oncol. 2017 Nov;14(11):647. - PMID 28948976